1. Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms
   Huiping Shi et al, 2016, Tumor Biology CrossRef
2. The Role of the RANKL/RANK Axis in the Prevention and Treatment of Breast Cancer with Immune Checkpoint Inhibitors and Anti-RANKL
   Aristofania Simatou et al, 2020, International Journal of Molecular Sciences CrossRef
3. Comprehensive Mapping of Key Regulatory Networks that Drive Oncogene Expression
   Lin Lin et al, 2020, Cell Reports CrossRef
4. Mangiferin enhances the sensitivity of human multiple myeloma cells to anticancer drugs through suppression of the nuclear factor κB pathway
   TOMOYA TAKEDA et al, 2016, International Journal of Oncology CrossRef
5. miRNAs as biomarkers of therapeutic response to HER2-targeted treatment in breast cancer: A systematic review
   Thanh Hoa Vo et al, 2024, Biochemistry and Biophysics Reports CrossRef
6. Lapatinib- and fulvestrant-PAMAM dendrimer conjugates promote apoptosis in chemotherapy-induced senescent breast cancer cells with different receptor status
   Anna Lewińska et al, 2022, Biomaterials Advances CrossRef
7. RANKL Signaling and ErbB Receptors in Breast Carcinogenesis
   Ilianna Zoi et al, 2016, Trends in Molecular Medicine CrossRef
8. 2‐(6‐Hydroxyhexylthio)‐5,8‐dimethoxy‐1,4‐naphthoquinone Induces Apoptosis through ROS‐Mediated MAPK, STAT3, and NF‐κB Signalling Pathways in Lung Cancer A549 Cells
   Gui-Nan Shen et al, 2020, Evidence-Based Complementary and Alternative Medicine CrossRef
9. EGF receptor uses SOS1 to drive constitutive activation of NFκB in cancer cells
   Sarmishtha De et al, 2014, Proceedings of the National Academy of Sciences CrossRef